Fatemeh Kazemi-Lomedasht - Venom & Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, ۱۳۱۶۹۴۳۵۵۱, Iran
serge muyldermans - Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, ۱۰۵۰ Brussels, Belgium
Mahdi Habibi-Anbouhi - National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, ۱۳۱۶۹۴۳۵۵۱, Iran
Mahdi Behdani - Venom & Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, ۱۳۱۶۹۴۳۵۵۱, Iran

Objective(s): Nanobodies, the single domain antigen binding fragments of heavy chain-only antibodies occurring naturally in camelid sera, are the smallest intact antigen binding entities. Their minimal size assists in reaching otherwise largely inaccessible regions of antigens. However, their camelid origin raises a possible concern of immunogenicity when used for human therapy. Humanization is a promising approach to overcome the problem.   Materials and Methods: Here, we designed a humanized version of previously developed nanobody (anti vascular endothelial growth factor nanobody), evaluated and compared its predicted ۳D structure, affinity and biological activity with its original wild type nanobody. Results: Our in silico results revealed an identical ۳D structure of the humanized nanobody as compare to original nanobody. In vitro studies also demonstrated that the humanization had no significant visible effect on the nanobody affinity or on its biological activity.  Conclusion: The humanized nanobody could be developed and proposed as a promising lead to target pathologic angiogenesis.

Angiogenesis, Antibody engineering, Humanization, Nanobody, VEGF